BioMatrix SpRx Selected as Authorized Provider of Hemlibra


BIOMATRIX SPRX SELECTED AS AUTHORIZED PROVIDER OF HEMLIBRA

First New Product for Hemophilia Inhibitor Patients in Nearly 20 Years

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – December 14, 2017 – BioMatrix SpRx today announced they have been selected as an authorized specialty pharmacy provider of Genentech’s new drug, Hemlibra (emicizumab-kxwh). The product is indicated for pediatric and adult patients who have hemophilia A with inhibitors.

Receiving Breakthrough Therapy Designation by the FDA in 2015, Hemlibra is the first self-administered, subcutaneous therapy for hemophilia. Data from ongoing clinical studies indicates once weekly injections substantially reduce bleed rates. To review information regarding Hemlibra, including the full list of authorized providers, visit the Genentech Hemlibra webpage. www.hemlibra.com  

Chief Clinical Officer David McCormick shares, “We are thrilled to partner with Genentech to offer Hemlibra. We have a long history of supporting patients with inhibitors and understand the unique challenges this community faces. We have witnessed the quality of life improvements this drug can provide, and are so proud to play our role in helping patients experience better health.”

To refer your patients to BioMatrix for Hemlibra therapy, please contact the pharmacy directly at 877-337-3002, online, or by completing a patient referral form.  

About BioMatrix SpRx
BioMatrix SpRx, a portfolio company of Acon Investments and Triton Pacific Capital Partners, LLC., offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions.  Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life.  The current BioMatrix family of companies includes Matrix Health Group, Factor Support Network, Medex BioCare, BiologicTx, and Elwyn Pharmacy Group.

BioMatrix Family of Companies Expands with Acquisition of Elwyn Pharmacy Group


Purchase Doubles Company Size And Adds Therapeutic Categories To Portfolio Of Services

Weston, FL – November 8, 2017BioMatrix SpRx, a growing leader in the specialty pharmacy industry, today announced the acquisition of Elwyn Pharmacy Group in Garnet Valley, Pennsylvania, 30 miles southwest of Philadelphia.

BioMatrix offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions. The growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. BioMatrix excels in providing services for hemophilia and bleeding disorders, transplant therapy, IVIg and specialty care, and digital health technology.

Elwyn Pharmacy Group provides medications and supportive services for patients living with hard to treat disease states with the goal of achieving optimal patient outcomes. This is realized through compliance and individualized therapy management in an environment that maximizes patient satisfaction and adherence. Elwyn’s expertise in neurological and auto-immune disorders, fertility, oncology, and other chronic conditions has made them a leader in the specialty pharmacy industry.

As a result of this transaction, BioMatrix has expanded their services into complementary therapeutic categories requiring the same high-touch services they are accustomed to providing. BioMatrix’s national footprint increases to 11 pharmacy locations, nationwide, in key metropolitan locations. Elwyn joins the rapidly growing family of companies that comprise

BioMatrix including Matrix Health Group, Factor Support Network, Medex BioCare, and BiologicTx.

“The acquisition of Elwyn Pharmacy Group complements our strategy of bringing together leaders in the specialty pharmacy industry to provide comprehensive, compassionate care to patients living with complex, chronic diseases, “stated Bruce Greenberg, Chief Executive Officer, BioMatrix SpRx. “We are pleased to welcome Elwyn and their experienced staff to the BioMatrix family.”

“BioMatrix and Elwyn share very similar values. The success of both companies is rooted in our collaborative, compassionate patient-centered approach,” stated Nicholas Karalis, Chief Executive Officer, Elwyn Pharmacy Group. “Together, we expand our ability to provide a high level of individualized, focused care to patients living with a chronic condition. We are extremely excited to be part of this larger organization.”

Additional information on BioMatrix and Elwyn can be found at www.biomatrixsprx.com and www.elwynspecialtycare.com, respectively.

About BioMatrix SpRx

BioMatrix SpRx, a portfolio company of Acon Investments and Triton Pacific Capital Partners, LLC., offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes Matrix Health Group, Factor Support Network, Medex BioCare, BiologicTx.

About Elwyn Pharmacy Group

Elwyn Pharmacy Group provides a complete range of specialty pharmacy and infusion services. We treat a wide array of complex disease states such as Multiple Sclerosis, Hepatitis C and other GI related diseases, Oncology/Cancer, bleeding disorders, Rheumatoid Arthritis, Psoriasis and HIV. The Elwyn Pharmacy Group includes Elwyn Pharmacy, Glen Rock Medical Pharmacy, Elwyn Specialty Care, and Med Center Specialty Pharmacy.